Postreperfusion Liver Biopsy as Predictor of Early Graft Dysfunction and Survival After Orthotopic Liver Transplantation [0.03%]
术后肝活检预测原位肝移植早期移植物功能障碍和生存率
Esteban Fuentes-Valenzuela,Javier Tejedor-Tejada,Félix García-Pajares et al.
Esteban Fuentes-Valenzuela et al.
Background: Postreperfusion liver biopsy (PRB) can assess the degree of ischemia/reperfusion injury (IRI) after orthotopic liver transplantation (OLT). The influence of IRI on graft outcomes and overall survival is contro...
Long-term Outcomes of Stool Transplant in Alcohol-associated Hepatitis-Analysis of Clinical Outcomes, Relapse, Gut Microbiota and Comparisons with Standard Care [0.03%]
粪便移植治疗酒精性肝炎的长期疗效分析：临床转归、复发、肠道菌群及与标准治疗比较
Cyriac A Philips,Rizwan Ahamed,Sasidharan Rajesh et al.
Cyriac A Philips et al.
Background: Healthy donor fecal microbiota transplantation (FMT) was preliminarily shown to have clinical benefits in hepatic encephalopathy (HE), severe alcohol-associated hepatitis (SAH), and alcohol use disorder. Howev...
Long-Term Outcomes of Endoscopic Management of Patients with Symptomatic Portal Cavernoma Cholangiopathy with No Shuntable Veins for Surgery or Failed Surgery [0.03%]
无侧支静脉可手术或手术失败的门脉海绵样变性胆道病内镜治疗的长期疗效分析
Suprabhat Giri,Aditya Kale,Ankita Singh et al.
Suprabhat Giri et al.
Background and aim: Shunt surgery is the definitive treatment for symptomatic patients with portal cavernoma cholangiopathy (PCC), but few patients are non-surgical candidates or fail to improve even after surgery. This s...
Living Donor Liver Transplantation in a Cohort of Recipients With Left Ventricular Systolic Dysfunction [0.03%]
左室收缩功能不全受者的活体供肝移植
Pooja Bhangui,Prashant Bhangui,Manish Aneja et al.
Pooja Bhangui et al.
Background: Data on feasibility, management, and outcomes of liver transplantation (LT) in patients with pre-existing left ventricular systolic dysfunction (LVSD), severe coronary artery disease (CAD) or cirrhotic cardiom...
Knowledge, Attitude and Practice of Gastroenterologists and Hepatologists Regarding Vaccination in Patients with Chronic Liver Disease [0.03%]
胃肠病学家和肝病学家对慢性肝病患者接种疫苗的知识、态度和实践调查
Dibya L Praharaj,Bipadabhanjan Mallick,Preetam Nath et al.
Dibya L Praharaj et al.
Skin Changes in Cirrhosis [0.03%]
肝硬化患者的皮肤变化
Adhyatm Bhandari,Rahul Mahajan
Adhyatm Bhandari
Skin manifestations of systemic disorders give a clue to the organ involved and help identify the possible disease-causing injury. Skin changes of liver cirrhosis are not specific, as they may be seen in disorders not involving the liver. T...
Keith Siau,Anand V Kulkarni,Emad El-Omar
Keith Siau
In academia, peer-review refers to a fundamental quality control process whereby external experts (reviewers) are invited to provide unbiased critique of a paper (or other submitted material) and advise on suitability for publication. The p...
Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study [0.03%]
非酒精性脂肪肝病早期肠道屏障功能障碍的演示：概念验证研究
Kanav Kaushal,Samagra Agarwal,Sanchit Sharma et al.
Kanav Kaushal et al.
Background/aims: Gut-barrier dysfunction is well recognized in pathogenesis of both non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). However, comparison of components of this dysfunction betwee...
Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot Study [0.03%]
西地那非磷酸二酯酶5型抑制剂治疗阴茎勃起功能障碍能否改善代偿期慢性肝病男性的生活质量？一项前瞻性试点研究
Alok Kumar,Vivek Saraswat,Gaurav Pande et al.
Alok Kumar et al.
Background and aims: Erectile dysfunction (ED) is common in patients with compensated cirrhosis but its impact on the quality of life (QOL) is usually overlooked. This study aimed at determining the frequency of ED in mal...
Shekhar S Jadaun,Sanjiv Saigal
Shekhar S Jadaun
Chronic liver diseases (CLD) is one of the leading causes of morbidity and mortality. The overall life span of patients with CLD has increased and so is the number of surgical procedures these patients undergo. Pathophysiological and hemody...